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Patients with chronic hepatitis C (CHC) virus infection who have persistently normal alanine aminotransferase levels (PNALT)
have mild inﬂammation and ﬁbrosis in comparison to those with elevated ALT levels. The cellular immune responses to HCV
are mainly responsible for viral clearance and the disease pathogenesis during infection. However, since the innate and adaptive
immunesystemsare suppressed by various kinds of mechanismsinCHC patients,the immunopathogenesisofCHC patients with
PNALT is still unclear. In this review, we summarize the representative reports about the immune suppression in CHC to better
understand the immunopathogenesis of PNALT. Then, we summarize and speculate on the immunological aspects of PNALT
including innate and adaptive immune systems and genetic polymorphisms of HLA and cytokines.
1.Introduction
Hepatitis C virus (HCV) is noncytopathic virus that causes
chronic hepatitis and hepatocellular carcinoma (HCC) [1].
Approximately70–80%ofthose acutelyinfected will become
persistently infected with HCV [1]. Around 30% of CHC
patients exhibit PNALT and show milder disease activity and
slower progression to hepatic cirrhosis [2–6]. However, it is
reported that about 40% of these progress to the active stage
of inﬂammation, but the incidence of HCC in the PNALT
was lower than that in those with elevated ALT levels [7].
Cellular and humoral immune responses to HCV play an
important role in the pathogenesis of active and nonactive
chronic hepatitis [8].
Numerous studies have indicated that failure of the cel-
lularimmune response, including type 1 helper T cells (Th1)
hypo-responsiveness, cytotoxicT lymphocyte(CTL) exhaus-
tion, excessive function of CD4+ CD25+ FOXP3+ regula-
tory T cells, and failure of lymphoid cells via direct binding
and/or infection in B cells, T cells, NK cells, and DCs occurs
in CHC patients [9–21]. Since the liver damage in CHC is
mainly induced by Th1 and/or CTL related responses [22–
24], these responses might be strongly suppressed in PNALT.
Given theinvolvementof immune responses, genetic fac-
tors including polymorphism of HLA and cyotokine-related
genes could also contribute to the activity of inﬂammation
in CHC patients [25–37]. Many groups, including us, have
reported on the relationship between certain HLA and ALT
levels in CHC patients [25, 27–29]. Moreover, some groups
indicated the polymorphism of certain cytokines-related
genes contributed to the level of inﬂammation [30–37]. In
a genomewide association study (GWAS), IL28B polymor-
phism was shown to inﬂuence the outcome of Peg-IFN
and RBV therapy [38]. However, although the relationship
between IL28B polymorphism and PNALT is still unclear, a
possible relationship between IL28B polymorphism and the
activity of inﬂammation has been reported [39, 40].
Inthisreview, we focusedon thepossible immunopatho-
logical aspects of PNALT and summarize various studies
aboutthemechanism andgenetichost factors involvedinthe
immune suppression in CHC patients.
2.Mechanism ofImmune Suppression
inCHCPatients
2.1. Innate Immune System in Hepatocytes
2.1.1.ImmuneSuppressionin CH-C. Innateimmune systems
are important for the initial step of viral infection [41,
42]( Figure 1). Toll-like receptors (TLRs) are a family of2 Hepatitis Research and Treatment
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Figure 1:The schema ofinnate immunesuppressionin CHC is shown.The representative suppressive mechanismsare shownin this ﬁgure.
innate immune-recognition receptors that recognize molec-
ular patterns associated with microbial pathogens including
single and double-strand RNA. HCV interferes with the
innate immune response and the induction of IFN-beta
via the HCV NS3/4A protease activity, which inhibits the
phosphorylation of IRF-3, a key transcriptional regulator
of the IFN response [43, 44]. HCV NS3 protein interacts
directly with TBK1, and this binding results in the inhibition
of the association between TBK1 and IRF-3, which leads to
the inhibition of IRF-3 activation [45].
2.1.2. Immune Suppression in PNALT. However, since little is
knownaboutthedirectrelationship betweenthesuppression
of TLR signaling and PNALT, the level of TLR signaling
suppressionmight contributeto the immunopathogenesisof
PNALT.
2.2. Monocyte, NK, and NK-T Cells
2.2.1. Immune Suppression in CH-C. In addition to the in-
tracellular immune reaction of hepatocytes, monocytes, NK,
and NK-T cellsare responsible forthe rapid reaction in HCV
infection (Figure 1). Many groups have described that NK
and NK-T cells were suppressed in CHC patients [46–53].
However, whether NK and NK-T cells would be suppressed
in CHC patients is still controversial [48]. The various
backgrounds of CHC patients have resulted in controversial
ﬁndings [49]. The function of NK cells is regulated by
a balance of inhibitory and activating signals, which are
mediated bythediﬀerentialexpressionofreceptors.Takehara
and Hayashi recently reported that the expression of the
inhibitory receptorCD94/NKG2AisupregulatedonNKcells
in CHC patients [53]. Another group reported that exposure
to HCVcc modulates the pattern of cytokines produced by
NK cells, leading to reduced antiviral activity [47].
2.2.2. Immune Suppression in PNALT. Previously, it was
reported that HCV-core and NS3 protein triggered the
inﬂammatory pathway via TLR2, which might aﬀect viral
recognitionand activationofthe immune system[54]. Itwas
also reported that peripheral blood monocyte expression of
TLR2butnotofTLR4correlatedsigniﬁcantly withtheserum
ALT levels [55]. Concerning the mechanisms of monocyte-
suppression, it was clearly demonstrated that macrophage
cell lines expressing NS3, NS3/4A, NS4B, or NS5A inhibited
the activation of the TLR2, TLR4, TLR7, and TLR9 signaling
pathways.AmongtheHCVindividualproteins,NS5Abound
to MyD88, a major adaptor molecule in TLR, inhibited the
recruitment of interleukin-1 receptor-associated kinase 1 to
MyD88 and impaired thecytokine productionin response toHepatitis Research and Treatment 3
Dendritic cells




















Lost of proliferation control
Direct Evidence for PNALT
Disturbance of maturation
Disturbance of antigen presentation
In balance of cytokine secretion
Exhaustion of CTL









C D 1 9+Bc e l l
Figure 2: The schema of adaptive immune suppression in CHC is shown. The representative suppressive mechanisms are shown in this
ﬁgure.
TLR ligands [56]. These results indicated that the activation
of monocytes was probably suppressed in low ALT and
PNALT CHC patients.
2.3. Adaptive Immune Systems: T Cells,
B Cells, and Dendritic Cells
2.3.1. Immune-Suppression in CH-C. After the innate im-
mune period, the adaptive immune system including CD4+
T cells, CD8+ cyototoxic T cells, B cells, and dendritic cells
should be involved in a more eﬀective immune response to
HCV.
The HCV antigen-driven proliferation of CD4+ T cells
is weak in patients who develop persistent HCV infection
[57, 58]. It has been demonstrated that depletion of CD4+
T cells results in a weak CD8+ T cell response, which partly
controls viremia, followed byviral persistence in chimpanzee
infection studies [59]. In addition, an appropriate Th1
response is essential to eradicate HCV [60]. It has been
reportedthatanincreasedTh2cytokineresponse mayreduce
the inﬂammatory and biochemical activity [61]. Moreover,
various studies have indicated that failure of the adap-
tive immune response, including Th1 hypo-responsiveness,
CD8+ CTL exhaustion, excessive function of CD4+ CD25+
FOXP3+ regulatory T cells, and failure of lymphoid cell
via direct binding and/or infection in B cells, T cells, and
DCs occurs in CHC patients [9–21]. Previously, we reported
the direct suppressive eﬀect of HCV on T cell- and B cell-
immunity in CHC by using a lymphotropic HCV strain [14–
17]. However, since the contribution of lymphotropic HCV
to the pathogenesis of PNALT is still not clear, the biological
signiﬁcance of lymphotropic HCV needs to be analyzed in
future studies. Studies about the relationship between the
infectivity of lymphotropic HCV and PNALT are ongoing
in our laboratory. Tregs constitutively express CD25 (the
IL2 receptor alpha-chain) in the physiological state [62].
In human, this Tregs population, deﬁned as CD4+ CD25+
FOXP3+ cells, constitutes 5% to 10% of peripheral CD4+
T cells and has a broad repertoire that recognizes various
types of self and nonself antigen. Antigens induced by HCV
might induce Tregs to escape from immunological pressure
as reported in persistent infection of EB virus, hepatitis B
virus, and HIV [63–67]( Figure 2).
2.3.2. Immune Suppression in PNALT. More recently, Itose
et al. reported that the frequencies of naturally occurring-
Treg in CHC patients were signiﬁcantly higher than those
in healthy individuals. The FOXP3 and CTLA4 transcripts4 Hepatitis Research and Treatment
were higher in PNALT than those in CHC patients [21].
Another group also described that their suppressor ability
is stronger in patients with PNALT than that in those with
active CHC hepatitis [68]. These two studies could be direct
evidence about the relationship between PNALT and the
function of Tregs. Moreover, a unique subset of lymphocytes




3.1. HLA Polymorphism. CD8+ CTLs are able to recognize
viral antigens synthesized within infected cells in the form of
short peptides associated with HLA class I molecules [70].
On the other hand, CD4+Th cells are able to recognize anti-
gens associated with HLA class II molecules [70, 71]. Indi-
viduals that are heterozygous at HLA class I loci are able to
present a greater variety of antigenic peptides to CTL result-
ing in a broader immune response [72]. HLA class I het-
erozygosity was found at a higher rate in patients with slow
progression to AIDS in HIV-1 infection [73]. However, HLA
class I heterozygosity did not aﬀect the inﬂammatory levels
of CHC patients in our previous study [27]. The frequency
of HLA-A2 tended to be higher in patients with PNALT than
in those with elevated ALT level [27]. A speciﬁc HLA class
II allele has been reported to inﬂuence the disease severity
[25] or viral clearance in chronic hepatitis C [26]. Yoshizawa
et al. reported that the frequencies of DRB1∗12 (∗1201 and
∗1202), DQB1∗0301, and DRB3∗03 alleles were higher in
patients with asymptomatic HCV carriers than those in liver
cirrhosis patients [28]. Large-scale studies might be able to
verify the ethnic, gender, age, and other genetic factors and
determine the inﬂuence of the HLA allele on PNALT.
3.2. Cytokine-Related Gene Polymorphism. Numerous stud-
ies indicated that various kinds of cytokine-related gene
polymorphism were involved in the immunopathogenesis of
CHC. IL10 is a suppressive cytokine that could contribute
to the persistence of HCV infection and low inﬂammation
level in CHC. Mangia et al. reported that the IL-10 ATA
haplotype was more frequent in patients with spontaneous
HCV RNA clearance (36.0%) than that in patients with
persistent infection (23%) [74]. On the other hand, another
group reported that no eﬀect of IL-1beta and IL-10 gene
polymorphism on the degree of hepatocellular injury was
apparent based on the ALT levels [37]. However, a gender
eﬀect is clearly observed in women carrying the GG high
IL-10 producer genotype. The higher levels of IL-10 present
in such individuals are associated with a higher risk of
ineﬃcient clearance of the HCV and the development of a
chronic HCV infection together with a lower risk of pro-
gression to cirrhosis in female patients [75]. These reports
indicatedthatIL-10-related genepolymorphism might aﬀect
the level of inﬂammation in certain conditions. Another
important gene is CCR5Delta32. CCR5Delta32, a 32-base
pair deletion of the CC chemokine receptor (CCR) 5 gene,
is associated with slower human immunodeﬁciency virus
disease progression in heterozygotes and protection against
infection in homozygotes. Goulding et al. reported that
heterozygosity for CCR5delta32 was signiﬁcantly associated
with spontaneous hepatitis C viral clearance and with signif-
icantly lower hepatic inﬂammatory scores [33]. In addition
to these gene polymorphisms, polymorphism of TGF-beta,
T N F - a l f a ,I L 2 ,I F N - g ,a n dO A S - 1g e n e sm i g h tc o n t r i b u t e
to the level of inﬂammation [30–32, 35, 74]. More recently,
GWASrevealedpromisingresults.Agenomewideassociation
of IL28B with the response to pegylated interferon and
ribavirin was reported [38]. Then, another group reported
that diﬀerentcytokineproﬁles inducedby the IL28 polymor-
phism resulted in diﬀerent Interferon stimulated genes and
IL28 expression during chronic HCV infection [76]. They
reported that the expression of IL28, MxA, PKR, OAS1, and
ISG15 in hepatic cells was signiﬁcantly lower in patientswith
the response-favorable (rs8099917) T/T genotype compared
to those with T/G or G/G genotypes [76]. A future study
might be able to determine the relationship between IL28
polymorphism and PNALT.
4.ConcludingRemarks
In CHC patients, there are many kinds of immune-sup-
pressive mechanisms. However,althoughtheimmunopatho-
genesis of PNALT has not been clariﬁed yet, the complexities
of immune reactions likely contribute to the diﬃculties of
determining the detailed mechanisms of PNALT. Recently,
the technologies of GWAS, immunoassay with increased
numbers of multicolor ﬂow cytometry analysis, and chimera
mice with human hepatocytes and lymphocytes have been
developed. These technologies, together with previous data,
might be able to clarify the immunopathogenesis of PNALT
in CHC.
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